Timothy Henrich, MD

Associate Professor of Medicine in Residence
Department of Medicine
415-203-5518
Research Description: 

The Henrich Lab focuses on understanding how and why viruses (e.g., HIV-1, SARS-CoV-2) persist across the whole body and on the development of novel methods to eliminate or mitigate the negative impact of chronic viral infections on human health.

The Henrich Lab leads an interdisciplinary and collaborative research program with a strong focus on translational virology and infectious disease research; all these projects stem from a passion for challenging or creating paradigms regarding viral persistence and pushing technological envelopes to implement novel strategies to study viral-host interactions across the whole body. Until 2020 our research pursuits focused predominately on the field of HIV curative strategies, virology, and pioneering the use of novel technologies to assess viral reservoirs at the single-cell level in many tissues. Since the onset of the COVID-19 pandemic, we have expanded this work in HIV to include SARS-CoV-2 and Human Herpes Viruses with a focus on viral persistence and mechanisms by which viral infections lead to post-acute and long-term sequelae.

Another hallmark of our research program is incorporating a multidisciplinary and collaborative approach to team science. We realized very early on during the SARS-CoV-2 epidemic that to solve urgent clinical and research needs in a timely manner, inclusive collaborations without a major focus on individual gain were going to be needed to solve some of the major virological and other mechanistic problems facing the research and patient community. We conduct research for the benefit of our patients and community first and foremost.

Primary Thematic Area: 
Virology & Microbial Pathogenesis
Secondary Thematic Area: 
Immunology
Research Summary: 
Immunmodulatory, cytoreductive chemotherapeutic and stem cell transplantation approaches to HIV-1 cure. Design and implementation of novel nano/microtechnologies to characterize viral reservoirs.
Publications: 

Targeting the SARS-CoV-2 reservoir in long COVID.

The Lancet. Infectious diseases

Proal AD, Aleman S, Bomsel M, Brodin P, Buggert M, Cherry S, Chertow DS, Davies HE, Dupont CL, Deeks SG, Ely EW, Fasano A, Freire M, Geng LN, Griffin DE, Henrich TJ, Hewitt SM, Iwasaki A, Krumholz HM, Locci M, Marconi VC, Mehandru S, Muller-Trutwin M, Painter MM, Pretorius E, Price DA, Putrino D, Qian Y, Roan NR, Salmon D, Tan GS, VanElzakker MB, Wherry EJ, Van Weyenbergh J, Yonker LM, Peluso MJ

Longitudinal changes in the transcriptionally active and intact HIV reservoir after starting ART during acute infection.

Journal of virology

Janssens J, Wedrychowski A, Kim SJ, Isbell C, Hoh R, Pillai SK, Henrich TJ, Deeks SG, Roan NR, Lee SA, Yukl SA

Galectin-9 Levels as a Potential Predictor of Intact HIV Reservoir Decay.

The Journal of infectious diseases

Serrano-Villar S, Gala A, Bacchetti P, Hoh R, di Germanio C, Cohn LB, Henrich TJ, Hunt PW, Laird GM, Pillai SK, Deeks SG, Peluso MJ

COVID-19 clinical presentation, management, and epidemiology: a concise compendium.

Frontiers in public health

Maison DP, Tasissa H, Deitchman A, Peluso MJ, Deng Y, Miller FD, Henrich TJ, Gerschenson M

Inflammatory Monocytes Increase Prior to Detectable HIV-1 Rebound Viremia.

bioRxiv : the preprint server for biology

Farrell-Sherman A, de la Force N, Prator C, Valieris R, Azam W, Da Silva I, Deeks SG, Thanh C, Bosch R, Henrich TJ, Cohn L